Evidence map›Paper›PMID 39384196›Full record

ArticleJournal for immunotherapy of cancer2024

Novel H-2D

James McAuliffe, Silvia Panetti, Emily Steffke, Amanda Wicki, Vinnycius Pereira-Almeida, Laurine Noblecourt, Yushu Hu, Shi Yu William Guo, Julie Lesenfants, Ramiro Andrei Ramirez-Valdez and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

James McAuliffe *Ludwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0002-4858-3191
Silvia Panetti *Ludwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0003-0176-7636
Emily SteffkeLudwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Amanda WickiLudwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Oxford, UK.ORCID http://orcid.org/0009-0001-7779-932X
Vinnycius Pereira-AlmeidaLudwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Laurine NoblecourtLudwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Yushu HuLudwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Shi Yu William GuoLudwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Julie Lesenfantsde Duve Institute, UCLouvain, Brussels, Belgium.
Ramiro Andrei Ramirez-ValdezLudwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Vineethkrishna ChandrasekarLudwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Maryam AhmadLudwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Vincent Stroobantde Duve Institute, UCLouvain, Brussels, Belgium.
Nathalie Vigneronde Duve Institute, UCLouvain, Brussels, Belgium.
Benoit J Van den Eynde *Ludwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Oxford, UK carol.leung@immonc.ox.ac.uk benoit.vandeneynde@ludwig.ox.ac.uk.
Carol Sze Ki Leung *Ludwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Oxford, UK carol.leung@immonc.ox.ac.uk benoit.vandeneynde@ludwig.ox.ac.uk.ORCID http://orcid.org/0000-0002-1545-7228

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMelanoma antigen gene (MAGE)-type antigens are promising targets for cancer immunotherapy as they are expressed in cancer cells but not in normal tissues, except for male germline cells. The mouse P1A antigen shares this MAGE-type expression pattern and has been used as a target antigen in preclinical tumor models aiming to induce antitumor CD8

methodsWe employed a heterologous prime-boost vaccination strategy based on a chimpanzee adenovirus (ChAdOx1) and a modified vaccinia Ankara (MVA) encoding P1A, to induce P1A-specific T-cell responses in C57BL/6 mice. Vaccine-induced responses were measured by intracellular cytokine staining and multiparameter flow cytometry. We mapped the immunogenic CD8 epitope and cloned the cognate T-cell receptor (TCR), which we used for adoptive cell therapy.

resultsChAdOx1/MVA-P1A vaccination induces a strong P1A-specific CD8

conclusionsWe identified the first CD8

Indexed as

Cancer VaccinesCD8-Positive T-LymphocytesEpitopes, T-LymphocyteMice, Inbred C57BLAnimalsAntigens, NeoplasmCell Line, TumorFemaleH-2 AntigensHistocompatibility Antigen H-2DMiceAntigens, NeoplasmCancer VaccinesEpitopes, T-LymphocyteH-2 AntigensHistocompatibility Antigen H-2DAdoptive cell therapy - ACTMajor histocompatibility complex - MHCT cellT cell Receptor - TCRVaccine

Identifiers

PMID39384196
PMCPMC11474967

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.